FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without palbociclib (Ibrance, Pfizer), was approved for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression during or after